Drug interactions
Larotrectinib + Liposomal doxorubicin
Severity: Minor
Larotrectinib and Liposomal doxorubicin: minor interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Larotrectinib is a CYP3A4 substrate with only weak inhibitory effects, and a relevant increase in doxorubicin exposure is not expected. No documented clinical interaction exists.
What this interaction means in plain words
Larotrectinib and Liposomal doxorubicin have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.
Larotrectinib belongs to Oncology; Liposomal doxorubicin belongs to Oncology.
Why it happens
Possible weak CYP3A4 inhibition; not clearly established.
What to do
No dose change is needed; monitor standard hematologic and cardiac parameters.
What to ask your pharmacist
- Is there anything I should notice while taking both?
- Do I need to tell my doctor at the next visit?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Larotrectinib and Liposomal doxorubicin, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Liposomal doxorubicin
- Dengue vaccine + Liposomal doxorubicin Contraindicated
- Belatacept + Liposomal doxorubicin Major
- Cyclosporine + Liposomal doxorubicin Major
- Dronedarone + Liposomal doxorubicin Major
- Elvitegravir / cobicistat / emtricitabine / tenofovir df + Liposomal doxorubicin Major
- Fingolimod + Liposomal doxorubicin Major
Other interactions of Larotrectinib
Frequently asked questions
Can I take Larotrectinib with Liposomal doxorubicin?
MediHelp rates the interaction as minor. Larotrectinib and Liposomal doxorubicin have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. Larotrectinib is a CYP3A4 substrate with only weak inhibitory effects, and a relevant increase in doxorubicin exposure is not expected. No documented clinical interaction exists.
How serious is the interaction between Larotrectinib and Liposomal doxorubicin?
MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: No dose change is needed; monitor standard hematologic and cardiac parameters.
What other medicines interact with Liposomal doxorubicin?
MediHelp also lists interactions of Liposomal doxorubicin with, for example, Dengue vaccine, Belatacept, Cyclosporine. The full list is on the Liposomal doxorubicin page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
